Morphic Holding, Inc. (MORF): Price and Financial Metrics

Morphic Holding, Inc. (MORF): $27.17

0.58 (+2.18%)

POWR Rating

Component Grades








Add MORF to Watchlist
Sign Up

Industry: Biotech




#325 of 347

in industry

MORF Price/Volume Stats

Current price $27.17 52-week high $63.08
Prev. close $26.59 52-week low $19.34
Day low $26.29 Volume 694,300
Day high $28.05 Avg. volume 642,311
50-day MA $22.32 Dividend yield N/A
200-day MA $43.61 Market Cap 1.35B

MORF Stock Price Chart Interactive Chart >


  • MORF scores best on the Value dimension, with a Value rank ahead of 36% of US stocks.
  • The strongest trend for MORF is in Quality, which has been heading down over the past 177 days.
  • MORF ranks lowest in Stability; there it ranks in the 2nd percentile.

MORF Stock Summary

  • MORF's price/sales ratio is 182.43; that's higher than the P/S ratio of 98.41% of US stocks.
  • With a year-over-year growth in debt of -58.39%, MORPHIC HOLDING INC's debt growth rate surpasses only 4.25% of about US stocks.
  • Revenue growth over the past 12 months for MORPHIC HOLDING INC comes in at -91.03%, a number that bests merely 1.64% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to MORF, based on their financial statements, market capitalization, and price volatility, are ACRS, CMRX, ANAB, DNLI, and NTLA.
  • Visit MORF's SEC page to see the company's official filings. To visit the company's web site, go to

MORF Valuation Summary

  • In comparison to the median Healthcare stock, MORF's price/sales ratio is 4636.84% higher, now standing at 180.
  • MORF's price/earnings ratio has moved up 12.8 over the prior 54 months.

Below are key valuation metrics over time for MORF.

Stock Date P/S P/B P/E EV/EBIT
MORF 2023-11-20 180.0 1.7 -8.8 -8.3
MORF 2023-11-17 174.9 1.6 -8.6 -8.0
MORF 2023-11-16 172.7 1.6 -8.5 -7.9
MORF 2023-11-15 174.0 1.6 -8.5 -8.0
MORF 2023-11-14 169.9 1.6 -8.3 -7.8
MORF 2023-11-13 156.1 1.4 -7.7 -7.1

MORF's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MORF has a Quality Grade of C, ranking ahead of 29.24% of graded US stocks.
  • MORF's asset turnover comes in at 0.114 -- ranking 252nd of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows MORF's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.114 1 -1.111
2021-03-31 0.150 1 -0.797
2020-12-31 0.199 1 -0.595
2020-09-30 0.170 1 -0.597
2020-06-30 0.079 1 -0.807
2020-03-31 0.072 1 -0.604

MORF Price Target

For more insight on analysts targets of MORF, see our MORF price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $100.50 Average Broker Recommendation 1.4 (Strong Buy)

Morphic Holding, Inc. (MORF) Company Bio

Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.

MORF Latest News Stream

Event/Time News Detail
Loading, please wait...

MORF Latest Social Stream

Loading social stream, please wait...

View Full MORF Social Stream

Latest MORF News From Around the Web

Below are the latest news stories about MORPHIC HOLDING INC that investors may wish to consider to help them evaluate MORF as an investment opportunity.

Wall Street Analysts See a 150.17% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?

The mean of analysts' price targets for Morphic Holding, Inc. (MORF) points to a 150.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | December 1, 2023

We're Not Very Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | November 23, 2023

Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 160.84%: Read This Before Placing a Bet

The consensus price target hints at a 160.8% upside potential for Morphic Holding, Inc. (MORF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | November 15, 2023

Morphic to Present at November Investor Conferences

WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the upcoming Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference. Jefferies London Healthcare Conference Fireside Chat Date: Tuesday, November 14, 2023Time: 5:00 PM GMT/12:00 PM ETA live webcast of

Yahoo | November 10, 2023

Morphic Holding, Inc. (MORF) Moves to Buy: Rationale Behind the Upgrade

Morphic Holding, Inc. (MORF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | November 9, 2023

Read More 'MORF' Stories Here

MORF Price Returns

1-mo 32.60%
3-mo -49.88%
6-mo -54.78%
1-year 4.14%
3-year -17.62%
5-year N/A
YTD 1.57%
2022 -43.54%
2021 41.22%
2020 95.51%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!